查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
肝硬化治疗市场规模、份额和成长分析（按疾病类型、治疗类型、最终用户和地区划分）—2026-2033年产业预测
市场调查报告书
商品编码
1899126

肝硬化治疗市场规模、份额和成长分析（按疾病类型、治疗类型、最终用户和地区划分）—2026-2033年产业预测

Liver Cirrhosis Treatment Market Size, Share, and Growth Analysis, By Disease Type (Alcoholic Cirrhosis, Atrophic Cirrhosis), By Treatment Type (Immunosuppressants, Antibiotics), By End User, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 218 Pages | 商品交期: 3-5个工作天内

价格
简介目录

全球肝硬化治疗市场规模预计在 2024 年达到 189 亿美元，从 2025 年的 201.1 亿美元增长到 2033 年的 330.3 亿美元，在预测期（2026-2033 年）内复合年增长率为 6.4%。

全球肝硬化治疗市场正积极应对因生活方式改变、酒精消费量增加和不良饮食习惯而日益严峻的肝病挑战。慢性肝病影响全球约15亿人，其盛行率显示对创新治疗方案的需求不断增长。乙型肝炎仍是肝硬化和肝细胞癌的主要病因，且与疾病相关的死亡率极高。影响市场成长的关键趋势是全球肝病发生率的上升，尤其是非酒精性脂肪性肝病（NAFLD），预计其发病率将呈指数级增长。随着全球对肝病的认识与诊断水准不断提高，以及各大製药公司大力投资研发新治疗方法，市场正呈现扩张迹象。

全球肝硬化治疗市场驱动因素

肝病在全球的流行仍然是一个重大问题，主要原因包括久坐不动的生活方式、缺乏运动和不健康的饮食习惯。此外，人口老化以及肝炎和非酒精性脂肪肝（NAFLD）等自体免疫疾病的增加，导致需要治疗的患者人数不断增加。同时，酒精消费量的上升也加剧了肝病的发生率。随着医疗机构努力满足治疗方法需求，预计透过与生物技术公司和研究机构合作，药物和医疗设备研发方面的创新将推动肝病治疗市场的发展。这种竞争格局将为相关人员创造众多机会，并推动市场成长。

全球肝硬化治疗市场面临的限制因素

全球肝硬化治疗市场面临许多重大挑战，阻碍其成长。有效治疗肝病所需的高昂药物、治疗和手术费用是市场发展的主要障碍。医疗资源匮乏，尤其是在农村和医疗服务不足的地区，加剧了这一问题，而公众和医疗服务提供者对肝病及其症状的认知不足则使情况更加恶化。此外，与酒精和细菌感染相关的某些肝病所存在的社会污名也使情况更加复杂。肝臟移植的挑战、严格的监管要求以及研发开发平臺缺乏创新药物也限制了市场发展。治疗所需的高昂费用是限制整个市场发展的因素之一。

全球肝硬化治疗市场趋势

全球肝硬化治疗市场正经历显着成长，这主要得益于研发投入的激增，这些投入旨在开发新的治疗方案和改进诊断技术。人们对肝病的认识不断提高，预防服务的普及以及治疗资金的增加，凸显了早期诊断和治疗这些疾病的紧迫性。此外，人口老化、医疗基础设施的改善以及新兴市场可支配收入的成长等人口结构变化也促进了市场扩张。外科手术和非侵入性放射介入技术的进步进一步拓展了治疗选择，这些因素共同为创新肝病治疗创造了有利环境。

目录

介绍

  • 调查目标
  • 调查范围
  • 定义

调查方法

  • 资讯收集
  • 二手资料和一手资料方法
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分市场机会分析

市场动态与展望

  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特分析

关键市场考察

  • 关键成功因素
  • 竞争程度
  • 关键投资机会
  • 市场生态系统
  • 市场吸引力指数（2025）
  • PESTEL 分析
  • 总体经济指标
  • 价值链分析
  • 定价分析

全球肝硬化治疗市场规模（按疾病类型和复合年增长率划分）（2026-2033 年）

  • 酒精性肝硬化
  • 萎缩性肝硬化
  • 胆汁性肝硬化
  • 病因不明的肝硬化

全球肝硬化治疗市场规模（按疗法和复合年增长率划分）（2026-2033 年）

  • 免疫抑制剂
  • 抗生素
  • 疫苗
  • 抗病毒药物
  • 皮质类固醇

全球肝硬化治疗市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

  • 医院药房
  • 零售药房
  • 其他的

全球肝硬化治疗市场规模及复合年增长率（2026-2033）

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前五大公司对比
  • 主要企业的市场定位（2025 年）
  • 主要市场参与者所采取的策略
  • 近期市场趋势
  • 公司市占率分析（2025 年）
  • 主要企业公司简介
    • 公司详情
    • 产品系列分析
    • 依业务板块进行公司股票分析
    • 2023-2025年营收年比比较

主要企业简介

  • Gilead Sciences（United States）
  • Pfizer Inc.（United States）
  • Merck & Co., Inc.（United States）
  • Novartis AG（Switzerland）
  • F. Hoffmann-La Roche Ltd（Switzerland）
  • Takeda Pharmaceutical Company Limited（Japan）
  • AstraZeneca（United Kingdom）
  • Bayer AG（Germany）
  • Sanofi（France）
  • AbbVie Inc.（United States）
  • GlaxoSmithKline PLC（United Kingdom）
  • Bristol-Myers Squibb Company（United States）
  • Alnylam Pharmaceuticals Inc.（United States）
  • Viking Therapeutics（United States）
  • Galectin Therapeutics Inc.（United States）
  • Akero Therapeutics, Inc.（United States）
  • NGM Biopharmaceuticals, Inc.（United States）
  • Poxel SA（France）

结论与建议

简介目录
Product Code: SQMIG35A2887

Global Liver Cirrhosis Treatment Market size was valued at USD 18.9 Billion in 2024 and is poised to grow from USD 20.11 Billion in 2025 to USD 33.03 Billion by 2033, growing at a CAGR of 6.4% during the forecast period (2026-2033).

The global liver cirrhosis treatment market is responding to increasing challenges posed by liver disease, driven by lifestyle changes, rising alcohol consumption, and poor dietary habits. The prevalence of chronic liver disease, which affects approximately 1.5 billion individuals worldwide, highlights the growing urgency for innovative therapeutic solutions. Hepatitis B remains a significant contributor to liver cirrhosis and hepatocellular carcinoma, with alarming mortality rates linked to the disease. Key trends influencing market growth include the increasing global incidence of liver conditions, particularly non-alcoholic fatty liver disease (NAFLD), which is expected to surge considerably. With major pharmaceutical companies investing heavily in research to develop new treatments, the market is poised for expansion as awareness and diagnosis of liver diseases continue to improve globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liver Cirrhosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liver Cirrhosis Treatment Market Segments Analysis

Global Liver Cirrhosis Treatment Market is segmented by Disease Type, Treatment Type, End User and region. Based on Disease Type, the market is segmented into Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis and Cryptogenic Cirrhosis. Based on Treatment Type, the market is segmented into Immunosuppressants, Antibiotics, Vaccines, Anti-viral drugs and Corticosteroids. Based on End User, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liver Cirrhosis Treatment Market

The prevalence of liver disease continues to be a significant global concern, primarily due to factors such as sedentary lifestyles, inadequate physical activity, and poor dietary habits. This, combined with an aging population and the rise of autoimmune conditions like hepatitis and non-alcoholic fatty liver disease, has led to a growing number of patients requiring treatment. Furthermore, increasing alcohol consumption has contributed to the higher incidence of liver-related ailments. The market for liver disease treatments is expected to flourish as healthcare organizations respond to the demand for therapies, driving innovation in drug and device development through partnerships with biotechnology and research firms. This competitive landscape is set to create numerous opportunities for stakeholders, thereby fueling market expansion.

Restraints in the Global Liver Cirrhosis Treatment Market

The Global Liver Cirrhosis Treatment market faces several significant challenges that impede its growth. The high costs associated with medications, procedures, and surgeries necessary for effective liver disease management are primary factors hindering market development. Limited healthcare access, particularly in rural and underserved regions, contributes to this issue, compounded by a general lack of awareness around liver diseases and their symptoms among both the public and healthcare providers. Additionally, the stigma surrounding certain liver conditions, such as those linked to alcohol or bacterial infections, further complicates matters. Furthermore, the difficulties associated with liver transplantation, strict regulatory requirements, and a shortage of innovative drugs in the research and development pipeline also restrict market advancement. The substantial financial burden required for treatment adds to the overarching market restraints.

Market Trends of the Global Liver Cirrhosis Treatment Market

The Global Liver Cirrhosis Treatment market is witnessing significant growth driven by a surge in research and development aimed at new therapeutic solutions and improved diagnostic techniques. Factors such as heightened awareness of liver diseases, preventive services, and funding for treatment underscore the urgency for early diagnosis and management of these conditions. Additionally, demographic shifts with an aging population, improved healthcare infrastructure, and rising disposable incomes in emerging markets contribute to market expansion. Advancements in surgical procedures and non-invasive radiology interventions further enhance treatment options, collectively fostering a robust environment for innovative liver disease management.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Liver Cirrhosis Treatment Market Size by Disease Type & CAGR (2026-2033)

  • Market Overview
  • Alcoholic Cirrhosis
  • Atrophic Cirrhosis
  • Biliary Cirrhosis
  • Cryptogenic Cirrhosis

Global Liver Cirrhosis Treatment Market Size by Treatment Type & CAGR (2026-2033)

  • Market Overview
  • Immunosuppressants
  • Antibiotics
  • Vaccines
  • Anti-viral drugs
  • Corticosteroids

Global Liver Cirrhosis Treatment Market Size by End User & CAGR (2026-2033)

  • Market Overview
  • Hospital Pharmacy
  • Retail Pharmacy
  • Other

Global Liver Cirrhosis Treatment Market Size & CAGR (2026-2033)

  • North America (Disease Type, Treatment Type, End User)
    • US
    • Canada
  • Europe (Disease Type, Treatment Type, End User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Disease Type, Treatment Type, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Disease Type, Treatment Type, End User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Disease Type, Treatment Type, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Gilead Sciences (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche Ltd (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline PLC (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Alnylam Pharmaceuticals Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Viking Therapeutics (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Galectin Therapeutics Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Akero Therapeutics, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • NGM Biopharmaceuticals, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Poxel SA (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations